oral galectin-3 inhibitor

Ph. I/II candidate in cancer and liver diseases

LLE and PK opt. from a prev. clinical candidate

J. Med. Chem.

Galecto Biotech, Gothenburg, SE

GB1211 chemical structure oral galectin-3 inhibitor - Galecto Biotech, Gothenburg, SE

Context. GB1211 (Galecto Biotech) is an oral galectin-3 inhibitor under development for fibrotic disease. First described in 1971, galectin-3, a unique subtype of a 15-member family of carbohydrate-binding proteins,…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: